Recently the function of SLC31A2 has been reported to associate with the development of lung adenocarcinoma, ovarian carcinoma, hepatocellular carcinoma, and sensitivity to Cisplatin [54–57]. Here, SLC31A2 is linked to ovarian carcinoma.